Latest News and Press Releases

AtaiBeckley will host a Virtual Investor Day on Friday, March 6, 2026, from 9:00 a.m. to 12:00 p.m. ET.

AtaiBeckley today announced the appointment of Michael Faerm as Chief Financial Officer, effective March 9, 2026.

Srinivas Rao, Co-Founder and Chief Executive Officer, and Jason Awe, VP of Investor Relations, will participate in several investor conferences.

AtaiBeckley announced participation in the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP)

AtaiBeckley provides its outlook for 2026 ahead of attendance at the J.P. Morgan 44th Annual Healthcare Conference

NEW YORK, Dec. 30, 2025 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by...

NEW YORK and AMSTERDAM, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient...

NEW YORK and AMSTERDAM, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or the “Company”), a clinical-stage biopharmaceutical company on a mission to transform...

NEW YORK and AMSTERDAM, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient...

BPL-003 (mebufotenin benzoate nasal spray) granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for treatment-resistant depression (TRD) Reported positive topline...